Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (1, 2.5, 5, 10 and 25 mg q.d. for 12 Days) of BI 1356 BS as Powder in the Bottle (PIB) in Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02183350
• Other study ID #: 1218.2
• Status: Completed
• Phase: Phase 1
• First received: July 4, 2014
• Last updated: July 4, 2014
• Start date: April 2005

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesNetherlands: Ministry of Health, Welfare and Sport
• Study type: Interventional

Clinical Trial Summary

The primary objective of the current study was to investigate the safety and tolerability of BI 1356 BS following administration of multiple rising oral doses of 1 mg, 2.5 mg, 5 mg, and 10 mg over 12 days in male patients with type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. primary completion date: August 2005
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

Male patients with proven diagnose of type 2 diabetes mellitus treated with diet and exercise only or with one (or two) oral hypoglycaemic agents besides glitazones

• Glycosylated haemoglobin A1 (HbA1c)

• = 8.5 % at screening for patients treated with diet and exercise and/or one oral hypoglycaemic agent or

• = 8.0 % at screening for patients treated with two oral hypoglycaemic agents

• Age =21 and Age =65 years

• BMI =18.5 and BMI =35 kg/m2 (Body Mass Index)

• Caucasian ethnicity

• Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice GCP and the local legislation

Exclusion Criteria:

• Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR) and Electrocardiogram (ECG)) deviating from normal and of not acceptable clinical relevance

• Clinically relevant concomitant diseases like renal insufficiency, cardiac insufficiency New York Heart Association (NYHA) II-IV, known cardiovascular diseases including hypertension > 160/110 mmHg, stroke and Transient ischaemic attack (TIA)

• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia and medically treated hypertension

• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders besides polyneuropathy

• Chronic or relevant acute infections (e.g. Human immunodeficiency virus (HIV), Hepatitis)

• History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)

• Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial except allowed co-medication

• Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial

• Participation in another trial with an investigational drug within two months prior to administration or during the trial

• Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)

• Inability to refrain from smoking on trial days

• Alcohol abuse (more than 60 g/day)

• Drug abuse

• Blood donation (more than 100 mL within four weeks prior to administration or during the trial)

• Excessive physical activities (within one week prior to administration or during the trial)

• Any laboratory value outside the reference range that is of not acceptable clinical relevance

• Change of drug dosing of allowed co-medication (anti-hypertensive agents, acetylic salicylic acid and statins) within the last 3 months

• Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 120 ms or QTcB > 450 ms or QT >500 ms

• Fasted blood glucose > 240 mg/dl (=13.3 mmol/L) on two consecutive days during washout

• Serum creatinine above upper limit of normal at screening

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2

Intervention

Drug:
• BI 1356 BS - single rising dose

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with adverse events		up to 28 days	No
Primary	Number of patients with abnormal findings in physical examination		up to 28 days	No
Primary	Number of patients with abnormal changes in Vital signs (blood pressure (BP), pulse rate (PR))		up to 28 days	No
Primary	Number of patients with abnormal changes in 12-lead ECG (electrocardiogram)		up to 28 days	No
Primary	Number of patients with abnormal changes in laboratory parameters		up to 28 days	No
Primary	Assessment of tolerability by investigator on a 4-point scale		up to 28 days	No
Secondary	Cmax (maximum concentration of the analyte in plasma)		predose, up to 456 h	No
Secondary	tmax (time from dosing to maximum concentration)		predose, up to 456 h	No
Secondary	AUC (area under the concentration-time curve of the analyte in plasma)		predose, up to 456 h	No
Secondary	Ae (amount of analyte that is eliminated in urine)		predose, up to 456 h	No
Secondary	fe (fraction of analyte excreted in urine)		up to 288 h	No
Secondary	CLR (renal clearance of the analyte in plasma)		up to 288 h	No
Secondary	Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval)		predose, up to 456 h	No
Secondary	Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)		predose, up to 456 h	No
Secondary	?z,ss (terminal rate constant in plasma at steady state)		predose, up to 456 h	No
Secondary	t1/2,ss (terminal half-life of the analyte in plasma at steady state)		predose, up to 456 h	No
Secondary	MRTpo,ss (mean residence time of the analyte in the body after 12 administrations at steady state)		predose, up to 456 h	No
Secondary	CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)		predose, up to 456 h	No
Secondary	Vz/F,ss (apparent volume of distribution during the terminal phase ?z following an extravascular dose at steady state)		predose, up to 456 h	No
Secondary	Changes in PTF (peak trough fluctuation)		up to 28 days	No
Secondary	RA,Cmax based on Cmax		predose, up to 456 h	No
Secondary	RA,AUC based on AUCt		predose, up to 456 h	No
Secondary	Changes in Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma		predose, up to 456 h	No
Secondary	Change in plasma glucose levels		up to 13 days	No

External Links

•   Link